Using cutting edge synthetic biology methods, we are optimizing a patent pending genome editing tool for the purpose of integrating very large pieces of DNA in to the genome. What that means for the future of therapeutic genome editing is that we are able to replace entire genes, spanning > 100kb. In the case of heritable diseases, individual point mutations are correctable with currently available genome editing technology, but there is a bottle neck in the FDA approval process. Each individual point mutation represents only a small subpopulation of those who carry a point mutation in a given gene. CasETTe (Cas enabled targeted transposase) aims to replace the complete gene, providing a therapeutic that can serve the whole population who carry disabling mutations in a particular gene.

With CasETTe, creativity is the only limit to genome editing. Large gene circuits carrying multiple functions and boolean logic and be seamlessly added to the genome.

In the case of aging and aging related disease, we envision editing particular proteins that serve as nodes of biological activity to provide increased resilience against the damaging forces that cause aging.